The Neuroendocrine Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Neuroendocrine Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Neuroendocrine Cancer. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Neuroendocrine Cancer and features dormant and discontinued products.

GlobalData tracks 149 drugs in development for Neuroendocrine Cancer by 128 companies/universities/institutes. The top development phase for Neuroendocrine Cancer is phase ii with 68 drugs in that stage. The Neuroendocrine Cancer pipeline has 144 drugs in development by companies and five by universities/ institutes. Some of the companies in the Neuroendocrine Cancer pipeline products market are: Merck, Pharma Mar and Ipsen.

The key targets in the Neuroendocrine Cancer pipeline products market include Cells Expressing Somatostatin Receptor Type 2 (SRIF1 or SSTR2), Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), and Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC

The key mechanisms of action in the Neuroendocrine Cancer pipeline product include Cytotoxic To Cells Expressing Somatostatin Receptor Type 2 (SRIF1 or SSTR2) with 15 drugs in Phase III. The Neuroendocrine Cancer pipeline products include 18 routes of administration with the top ROA being Intravenous and 15 key molecule types in the Neuroendocrine Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.

Neuroendocrine Cancer overview

A neuroendocrine cancer, often referred as a neuroendocrine tumor (NET) or neuroendocrine neoplasm, begins in the specialized cells of the body’s neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells. They are found throughout the body’s organs and help control many of the body’s functions. Hormones are chemical substances that are carried through the bloodstream to have a specific effect on the activity of other organs or cells in the body. Most NETs take years to develop and grow slowly. However, some NETs can be fast-growing.

For a complete picture of Neuroendocrine Cancer’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.